Skip to main content
Fig. 1 | Systematic Reviews

Fig. 1

From: Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis

Fig. 1

Boundaries of equivalence (dashed lines) for a two-sided 95% confidence interval of the treatment difference. A Equivalence margins for ACR20 (primary outcome). B Equivalence margins for HAQ-DI (co-primary outcome). If the summary 95% CI lies within the gray regions, the null hypothesis will be rejected, and equivalence will be claimed

Back to article page

Systematic Reviews

ISSN: 2046-4053